COPD Patient Data from a Randomized Trial Comparing Acetylcysteine and Ambroxol

Anonymized participant-level data from a prospective randomized open blinded endpoint (PROBE) trial conducted at RS Paru Respira Yogyakarta, Indonesia. The dataset includes participant characteristics, intervention allocation, and baseline and follow-up COPD Assessment Test and Cough Symptom Scores. It was published by Luthfiah Pertiwi on figshare under a CC-BY-4.0 license.

Use Cases

• Compare the effectiveness of N-acetylcysteine versus ambroxol based on changes in COPD Assessment Test scores.
• Analyze the relationship between patient characteristics and treatment outcomes based on demographic and comorbidity data.
• Model changes in cough symptom scores over time based on the calculated delta values provided.
• Assess patient adherence and follow-up status in a post-hospitalization clinical trial setting.

Strengths

• Data is anonymized to protect participant confidentiality, with identifiers replaced by study codes.
• Includes calculated change metrics (Δ) for both CAT and cough scores, facilitating outcome analysis.
• Dataset is provided to support reproducibility and secondary analysis of published findings.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 80.0 KB, indicating a limited scope and likely a small sample size.

Provenance

Source

figshare, authored by Luthfiah Pertiwi.

Collection Method

Collected from a prospective randomized open blinded endpoint (PROBE) clinical trial.

Freshness

Last updated 2026-05-30 08:35:30; freshness should be verified.

Geography

RS Paru Respira Yogyakarta, Indonesia.